Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Alzamend Neuro Inc (ALZN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: ALZN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $180
1 Year Target Price $180
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22.83% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.45M USD | Price to earnings Ratio - | 1Y Target Price 180 |
Price to earnings Ratio - | 1Y Target Price 180 | ||
Volume (30-day avg) 2 | Beta -0.28 | 52 Weeks Range 2.75 - 52.65 | Updated Date 07/10/2025 |
52 Weeks Range 2.75 - 52.65 | Updated Date 07/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1210.59 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -106.08% | Return on Equity (TTM) -1092.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2375585 | Price to Sales(TTM) - |
Enterprise Value 2375585 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.13 | Shares Outstanding 800954 | Shares Floating 715917 |
Shares Outstanding 800954 | Shares Floating 715917 | ||
Percent Insiders 3.22 | Percent Institutions 0.88 |
Upturn AI SWOT
Alzamend Neuro Inc
Company Overview
History and Background
Alzamend Neuro, Inc. (ALZN) is a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimeru2019s disease, bipolar disorder, major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). It was founded in 2016 and has been primarily engaged in research and development activities.
Core Business Areas
- Alzheimer's Disease Therapeutics: Developing AL001, a lithium-delivery system, and AL002, a cell-based therapeutic vaccine.
- Neuropsychiatric Disorder Therapeutics: Exploring treatments for bipolar disorder, MDD, and PTSD, leveraging the AL001 technology.
Leadership and Structure
The leadership team includes Dr. Milton u201cMJu201d Ezzati, CEO; Stephan Jackman, CFO. The company operates with a structure typical of a small, research-focused biopharmaceutical firm, heavily reliant on scientific expertise and clinical development personnel.
Top Products and Market Share
Key Offerings
- AL001 (Lithium-Delivery System): A patented ionic cocrystal composed of lithium and L-proline, designed to deliver lithium more efficiently and potentially with fewer side effects. It is in early-stage clinical trials. Market share is currently 0% as the product is not yet commercialized. Competitors include existing lithium treatments from various pharmaceutical companies.
- AL002 (Cell-Based Therapeutic Vaccine): An autologous dendritic cell immunotherapy designed to treat Alzheimeru2019s disease. It is also in early-stage development. Market share is currently 0% as the product is not yet commercialized. Competitors include other companies developing Alzheimer's vaccines and immunotherapies.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly in the areas of Alzheimeru2019s and neuropsychiatric disorders, is characterized by high unmet need and significant market potential. There's intense competition and high regulatory hurdles.
Positioning
Alzamend Neuro is a preclinical stage company aiming to innovate in drug delivery and immunotherapy for neurological disorders. Its competitive advantage hinges on the potential efficacy and safety benefits of its novel technologies, if proven in clinical trials.
Total Addressable Market (TAM)
The TAM for Alzheimer's therapeutics is projected to be in the billions of dollars annually. Alzamend's position is speculative, dependent on clinical trial outcomes, with the potential to capture a significant portion of the market if its products are successful.
Upturn SWOT Analysis
Strengths
- Novel drug delivery system (AL001)
- Innovative immunotherapy approach (AL002)
- Focus on high-need therapeutic areas
- Strong patent portfolio
Weaknesses
- Preclinical stage company with no revenue
- High cash burn rate
- Reliance on successful clinical trial outcomes
- Small market capitalization
Opportunities
- Positive clinical trial results could drive significant stock appreciation
- Partnerships with larger pharmaceutical companies
- Government grants and funding opportunities
- Expansion into other neurological indications
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger, more established companies
- Difficulty raising capital
Competitors and Market Share
Key Competitors
- LLY
- ABBV
- BIIB
- ACAD
- AXSM
Competitive Landscape
Alzamend Neuro faces intense competition from larger pharmaceutical companies with significantly more resources and established products. Alzamend relies on innovative science to disrupt the market. They have the first mover advantage on their product.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by expansion of research and development programs.
Future Projections: Future growth is contingent on successful clinical trial outcomes and regulatory approvals. Analyst projections are highly speculative at this stage.
Recent Initiatives: Recent initiatives include advancing AL001 into clinical trials and continuing preclinical development of AL002.
Summary
Alzamend Neuro is a high-risk, high-reward preclinical stage company focused on innovative treatments for neurological disorders. Its success hinges on positive clinical trial outcomes for its AL001 and AL002 programs. The company faces significant financial challenges due to its cash burn rate, and must navigate intense competition in the pharmaceutical industry, and is highly speculative.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports (where available)
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and is subject to change. Investing in preclinical stage companies is highly speculative and carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alzamend Neuro Inc
Exchange NASDAQ | Headquaters Atlanta, GA, United States | ||
IPO Launch date 2021-06-15 | CEO & Director Mr. Stephan Jackman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.alzamend.com |
Full time employees 4 | Website https://www.alzamend.com | ||
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.